News

Company News & Events

ORYZON to Regain Rights to ORY-1001 (RG6016)

20 July 2017

BARCELONA, SPAIN and CAMBRIDGE MA.

• Management to Host two Web Conferences today, July 20th
    - at 10:00 am CET in Spanish and
    - at 8:30 am ET in English

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that yesterday evening Roche informed Oryzon that due to a portfolio prioritization, it has decided to discontinue its involvement in the clinical development of the investigational Lysine Specific Demethylase-1 (LSD1) inhibitor ORY-1001 (RG6016) for the treatment of patients with acute myeloid leukemia (AML) and solid tumors pursuant to the license agreement between Oryzon and Roche dated April 1st, 2014.

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story